ImpediMed Ltd is primarily active in the healthcare industry.

The main competitors of ImpediMed Ltd in the market are [competitor names].

ImpediMed Ltd is an Australian-based medical technology company founded in 1999. The company specializes in the development and commercialization of bioimpedance spectroscopy (BIS) devices for non-invasive fluid management. ImpediMed's technology has applications in the areas of lymphedema management, early detection of secondary lymphedema, and monitoring of body composition in clinical and research settings. With a focus on improving patient outcomes, ImpediMed has established a strong reputation in the medical field. As a leading provider of BIS technology, ImpediMed continues to innovate and make advancements in the field of medical diagnostics and patient care.

ImpediMed Ltd, a leading medical technology company, has accomplished several significant milestones throughout its journey. The company successfully developed and commercialized its innovative bioimpedance spectroscopy technology, the L-Dex System. This revolutionary product enables early detection of lymphedema, a condition commonly associated with cancer treatment. ImpediMed also received FDA approval for its product, marking a crucial milestone in expanding its market reach. Furthermore, the company has made notable progress through strategic collaborations with prestigious medical institutions and key partnerships with renowned healthcare organizations. ImpediMed's commitment to advancing patient care, combined with its continuous technological advancements, showcases its substantial achievements in the medical technology industry.

ImpediMed Ltd is primarily present in several countries and regions worldwide. The company has a global presence with a focus on key markets including the United States, Australia, and Europe. ImpediMed operates in the healthcare industry, providing medical devices and solutions for the management and monitoring of lymphedema, heart failure, and body composition. With its innovative technologies and strong market penetration, ImpediMed continues to expand its presence and deliver its products to healthcare professionals and patients worldwide.

ImpediMed Ltd represents values of innovation, integrity, and dedication to improving healthcare outcomes. The company's corporate philosophy focuses on providing advanced and accurate medical devices and solutions for the assessment and monitoring of body composition and fluid status. ImpediMed is committed to delivering products that assist healthcare professionals in making informed decisions for better patient management. With a strong emphasis on research and development, ImpediMed continuously strives to revolutionize the field of bioimpedance spectroscopy, ensuring accurate and non-invasive measurements. By placing a significant emphasis on technological advancements, ImpediMed Ltd aims to transform patient care and improve overall health outcomes.

Analysts currently set an average price target of 0,05 AUD for the ImpediMed stock (median: 0,05 AUD), implying +1 111,2 % versus the latest price. The consensus is based on 8 analyst ratings.

ImpediMed Analyytikkojen kursstavoitteet 2026

8 analysts currently rate the ImpediMed stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect ImpediMed to generate revenue of 16,66 M AUD and earnings per share of −0,01 AUD.

ImpediMed Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the ImpediMed share trades at 0,00 EUR (0,00 AUD).

The ImpediMed share (IPD.AX) is listed on 2 stock exchanges, including: ASX (IPD.AX).

ImpediMed Ltd is a global company specializing in the development of medical devices and solutions for measuring lymphedema and other fluid accumulation in the body. The company was founded in 1999 and is headquartered in Brisbane, Australia. ImpediMed is divided into two main business segments - ImpediMed and Sozo. ImpediMed specializes in the development of bioimpedance devices, while Sozo specializes in the measurement of body fluids by combining bioimpedance with other technologies such as optical imaging and sonography. Sozo specifically addresses data-driven clinical problems by providing doctors and nurses with an objective, automated method for measuring edema. ImpediMed's bioimpedance technology is mainly used for monitoring edema and other conditions caused by irregular fluid accumulation. The device measures the electrical resistance in the tissue, allowing for an accurate determination of extracellular fluid, intracellular fluid, and body fat percentage. ImpediMed's Sozo system combines bioimpedance with other technologies. It provides accurate measurement of extracellular fluid, which is essential for the diagnosis, monitoring, and therapy management of various diseases, including lymphedema. ImpediMed also offers training on specific diseases for doctors and nursing staff. ImpediMed specializes in developing medical products for the field of oncology and lymphedema patients. The company also offers specialized post-care for oncology patients by supporting monitoring for edema, swelling, and body fluids. ImpediMed has established itself as a leading provider of edema monitoring solutions and operates in Europe, Asia, North America, and Australia. The company is committed to providing its customers with reliable and accurate diagnoses to enable a good quality of life for people suffering from various edema conditions. It collaborates with specialized physicians in various medical fields. Overall, ImpediMed is a successful company that has found a niche in the medical industry with its bioimpedance technology. The variety of products and solutions it offers, along with collaborations with specialized physicians, have contributed to its establishment as a leading player in edema monitoring in a short period of time.

odotettu liikevaihto ImpediMed on 16,66 M AUD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto ImpediMed on −21,92 M AUD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

ImpediMed:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,41. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan ImpediMed-osakkeen arvostusta.

ImpediMed:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,55. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii ImpediMed-osakkeen arvostuskennuslukuna.

ImpediMed:n Eulpool-laatuscore on 4/10.

ImpediMed:n ISIN on AU000000IPD8. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

ImpediMed:n ticker on IPD.AX. Tämä pörssinoteeraus käytetään ImpediMed-osakkeiden kauppaan pörssissä.

ImpediMed maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

ImpediMed kuuluu sektoriin 'Terveydenhuolto'.

ImpediMed:n osingot jaetaan valuutassa AUD.